Is Phio Pharmaceuticals Stock a Good Investment?
Phio Pharmaceuticals Investment Advice | PHIO |
- Examine Phio Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Phio Pharmaceuticals' leadership team and their track record. Good management can help Phio Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Phio Pharmaceuticals' business and its evolving consumer preferences.
- Compare Phio Pharmaceuticals' performance and market position to its competitors. Analyze how Phio Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Phio Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Phio Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Phio Pharmaceuticals Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Phio Pharmaceuticals Corp is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Phio Pharmaceuticals Stock
Researching Phio Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.4. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Phio Pharmaceuticals Corp recorded a loss per share of 22.68. The entity last dividend was issued on the 15th of January 2020. The firm had 1:9 split on the 5th of July 2024.
To determine if Phio Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Phio Pharmaceuticals' research are outlined below:
| Phio Pharmaceuticals generated a negative expected return over the last 90 days | |
| Phio Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (10.83 M) with loss before overhead, payroll, taxes, and interest of (7.01 M). | |
| Phio Pharmaceuticals Corp currently holds about 18.02 M in cash with (10.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32. | |
| Phio Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Phio Pharmaceuticals regains Nasdaq compliance post-reverse split - Investing.com |
Phio Pharmaceuticals Quarterly Long Term Debt |
|
Phio Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Phio Pharmaceuticals Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Phio Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Phio Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Phio Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-09 | 2023-09-30 | -1.43 | -1.14 | 0.29 | 20 | ||
2021-11-10 | 2021-09-30 | -3 | -3.36 | -0.36 | 12 | ||
2024-04-01 | 2024-03-31 | -1.3 | -0.85 | 0.45 | 34 | ||
2024-03-20 | 2023-12-31 | -1.3 | -0.85 | 0.45 | 34 | ||
2022-03-22 | 2021-12-31 | -3.84 | -3.24 | 0.6 | 15 | ||
2021-08-12 | 2021-06-30 | -3.12 | -2.4 | 0.72 | 23 | ||
2023-03-22 | 2022-12-31 | -3.24 | -2.4 | 0.84 | 25 | ||
2022-05-12 | 2022-03-31 | -3.6 | -2.28 | 1.32 | 36 |
Know Phio Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Phio Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Phio Pharmaceuticals Corp backward and forwards among themselves. Phio Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Phio Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-03-31 | 1.0 | Sabby Management Llc | 2024-03-31 | 0.0 | Citigroup Inc | 2023-12-31 | 0.0 | Renaissance Technologies Corp | 2024-03-31 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-03-31 | 0.0 | Geode Capital Management, Llc | 2023-12-31 | 0.0 | Anson Funds Management Lp | 2024-03-31 | 0.0 | Jpmorgan Chase & Co | 2023-12-31 | 0.0 | Virtu Financial Llc | 2024-03-31 | 30.9 K | Cetera Advisors Llc | 2024-03-31 | 30.4 K | Cetera Investment Advisers | 2024-03-31 | 30.4 K |
Phio Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.96 M.Market Cap |
|
Phio Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.16) | (1.21) | |
| Return On Capital Employed | (1.38) | (1.31) | |
| Return On Assets | (1.16) | (1.21) | |
| Return On Equity | (1.40) | (1.33) |
Determining Phio Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Phio Pharmaceuticals is a good buy. For example, gross profit margin measures Phio Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Phio Pharmaceuticals' profitability and make more informed investment decisions.
The data published in Phio Pharmaceuticals' official financial statements typically reflect Phio Pharmaceuticals' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Phio Pharmaceuticals' quantitative information. For example, before you start analyzing numbers published by Phio accountants, it's essential to understand Phio Pharmaceuticals' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Evaluate Phio Pharmaceuticals' management efficiency
Phio Pharmaceuticals Corp has return on total asset (ROA) of (0.6965) % which means that it has lost $0.6965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4523) %, meaning that it created substantial loss on money invested by shareholders. Phio Pharmaceuticals' management efficiency ratios could be used to measure how well Phio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of July 2024, Return On Tangible Assets is likely to drop to -1.21. In addition to that, Return On Capital Employed is likely to grow to -1.31. At this time, Phio Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 27th of July 2024, Total Current Assets is likely to grow to about 12.1 M, while Non Current Assets Total are likely to drop about 39.9 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 33.39 | 31.72 | |
| Tangible Book Value Per Share | 33.39 | 31.72 | |
| Enterprise Value Over EBITDA | 0.65 | 0.69 | |
| Price Book Value Ratio | 0.20 | 0.19 | |
| Enterprise Value Multiple | 0.65 | 0.69 | |
| Price Fair Value | 0.20 | 0.19 | |
| Enterprise Value | -6.9 M | -6.5 M |
The analysis of Phio Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Phio Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Phio Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 1.448 |
Basic technical analysis of Phio Stock
As of the 27th of July, Phio Pharmaceuticals holds the Coefficient Of Variation of (970.98), risk adjusted performance of (0.06), and Variance of 28.33. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Phio Pharmaceuticals, as well as the relationship between them.Phio Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Phio Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Phio Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Phio Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Phio Pharmaceuticals' Outstanding Corporate Bonds
Phio Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Phio Pharmaceuticals Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Phio bonds can be classified according to their maturity, which is the date when Phio Pharmaceuticals Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Bank of America Corp BondUS06051GFU85 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| CVS Health Corp Corp BondUS126650DE72 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Phio Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Phio Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.70) | |||
| Mean Deviation | 4.16 | |||
| Coefficient Of Variation | (970.98) | |||
| Standard Deviation | 5.32 | |||
| Variance | 28.33 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.61) | |||
| Total Risk Alpha | (1.12) | |||
| Treynor Ratio | (0.71) | |||
| Maximum Drawdown | 26.62 | |||
| Value At Risk | (8.51) | |||
| Potential Upside | 9.09 | |||
| Skewness | (0.13) | |||
| Kurtosis | 0.3605 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.70) | |||
| Mean Deviation | 4.16 | |||
| Coefficient Of Variation | (970.98) | |||
| Standard Deviation | 5.32 | |||
| Variance | 28.33 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.61) | |||
| Total Risk Alpha | (1.12) | |||
| Treynor Ratio | (0.71) | |||
| Maximum Drawdown | 26.62 | |||
| Value At Risk | (8.51) | |||
| Potential Upside | 9.09 | |||
| Skewness | (0.13) | |||
| Kurtosis | 0.3605 |
Consider Phio Pharmaceuticals' intraday indicators
Phio Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Phio Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 11348.14 | |||
| Daily Balance Of Power | 0.2692 | |||
| Rate Of Daily Change | 1.04 | |||
| Day Median Price | 3.81 | |||
| Day Typical Price | 3.87 | |||
| Price Action Indicator | 0.25 | |||
| Period Momentum Indicator | 0.14 |
Phio Pharmaceuticals Corporate Filings
S1 | 26th of July 2024 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
| 24th of July 2024 Other Reports | ViewVerify | |
8K | 12th of July 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 11th of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Phio Stock media impact
Far too much social signal, news, headlines, and media speculation about Phio Pharmaceuticals that are available to investors today. That information is available publicly through Phio media outlets and privately through word of mouth or via Phio internal channels. However, regardless of the origin, that massive amount of Phio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Phio Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Phio Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Phio Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Phio Pharmaceuticals alpha.
Phio Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Phio Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Phio Pharmaceuticals Corporate Management
| Jim Cardia | VP Operations | Profile | |
| Caitlin Kontulis | VP Secretary | Profile | |
| Dr MedSc | Interim Director | Profile | |
| Linda Mahoney | Senior Development | Profile |
Additional Information and Resources on Investing in Phio Stock
When determining whether Phio Pharmaceuticals Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phio Pharmaceuticals Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Phio Pharmaceuticals Corp Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (22.68) | Return On Assets (0.70) | Return On Equity (1.45) |
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Phio Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.